Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Business Activity | PASS |
| Debt Ratio (0.03%) | PASS |
| Cash Ratio (0.17%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-12 | 0.11 | Pending | — |
| 2026-05-13 | 0.12 | 0.07 | -39.1% |
| 2026-03-11 | 0.08 | 0.06 | -22.6% |
| 2025-11-10 | 0.09 | 0.09 | -2.7% |
| 2025-08-13 | 0.09 | 0.13 | +44.4% |
| 2025-05-14 | 0.07 | 0.07 | +3.7% |
| 2025-03-05 | 0.05 | 0.07 | +31.3% |
| 2024-11-13 | 0.07 | 0.07 | — |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $45.2M | $4.1M | $9.4M | $19.1M | $7.0M | 0.07 |
| 2025-12-31 | $44.7M | $3.6M | $8.8M | $17.0M | $3.6M | 0.06 |
| 2025-09-30 | $47.0M | $5.3M | $10.3M | $19.8M | $7.8M | 0.09 |
| 2025-06-30 | $44.8M | $7.4M | $9.7M | $18.9M | $7.1M | 0.13 |
| 2025-03-31 | $44.0M | $4.0M | $10.4M | $20.7M | $7.8M | 0.07 |
| 2024-12-31 | — | — | — | — | — | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Phoenix Financial Ltd. | 1.7M | $13.0M | 0.0% |
| Renaissance Technologies, LLC | 762.9K | $6.0M | 0.0% |
| Acadian Asset Management. LLC | 371.6K | $2.9M | 0.0% |
| ARK Investment Management, LLC | 269.6K | $2.1M | 0.0% |
| Two Sigma Investments, LP | 194.2K | $1.5M | 0.0% |
| Envestnet Asset Management Inc. | 166.1K | $1.3M | 0.0% |
| Huntleigh Advisors, Inc. | 155.5K | $1.2M | 0.0% |
| Marshall Wace LLP | 150.0K | $1.2M | 0.0% |
| Y.D. More Investments Ltd | 136.4K | $1.1M | 0.0% |
| Renaissance Group, LLC | 125.9K | $985.8K | 0.0% |
Buy
Hold
Sell
Strong Sell
$400.7M
1.78
0.201
4
$180.5M
$11.6M
0.0%
3.1%
1.00
2.74
0.0%
462
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.11 | Pending | — |
| 2026-05-13 | $0.12 | $0.07 | -39.1% |
| 2026-03-11 | $0.08 | $0.06 | -22.6% |
| 2025-11-10 | $0.09 | $0.09 | -2.7% |
| 2025-08-13 | $0.09 | $0.13 | +44.4% |
| 2025-05-14 | $0.07 | $0.07 | +3.7% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($13.00, 4 analysts) | |||
| 10 | $78.10 | +$51.90 (66%) | 4.4R |
| 50 | $390.50 | +$259.50 (66%) | 4.4R |
| 100 | $781.00 | +$519.00 (66%) | 4.4R |
| To Fair Value ($8.89) | |||
| 10 | $78.10 | +$10.80 (14%) | 0.9R |
| 50 | $390.50 | +$54.00 (14%) | 0.9R |
| 100 | $781.00 | +$108.00 (14%) | 0.9R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| CRBN | 0.412 |
| ARKK | 0.394 |
| SPTE | 0.392 |
| UMMA | 0.391 |
| ESGV | 0.391 |
| Ticker | Correlation |
|---|---|
| BAES.L | -0.174 |
| OEIHC.AB | -0.159 |
| MCLDF | -0.150 |
| CBD.AE | -0.146 |
| CBOE | -0.143 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500